

Alarming Growth in the Prevalence of Obesity to Propel the Growth of Anti-obesity Drugs Market in Future

Alarming Growth in the Prevalence of Obesity to Propel the Growth of Anti-obesity Drugs Market in Future, According to Research Nester.

BROOKYLN, 11230, UNITED STATES, December 12, 2017 /EINPresswire.com/ -- "<u>Anti-Obesity</u> <u>Drugs Market</u>: Global Demand Analysis & Opportunity Outlook 2021"

The <u>global anti-obesity drugs market</u> is segmented into product type such as prescription drugs and over the counter drugs. Among these segments, over the counter drugs segment is expected to occupy top position in overall anti-obesity drugs market during the forecast period. Further, easy availability of over-the-counter drugs in many nations is driving the major factor behind the growth of over the counter drug segment. Furthermore, major pharmaceutical industries such as GlaxoSmithKline are engaged in the development, manufacturing and marketing of



OTC anti-obesity drugs. This factor is expected to strengthen the market of over the counter antiobesity drugs.

Global anti-obesity drugs market is expected to flourish at a significant CAGR of 40.0% during the forecast period. Moreover, the global anti-obesity drugs market is predicted to garner noteworthy revenue by the end of 2021. Factors such as growing population of obese peoples, rising awareness about obesity related diseases, growing healthcare expenditure are anticipated to be the dynamic factor behind the growth of anti-obesity drugs market.

North America dominated the overall market of <u>anti-obesity drugs in 2016</u>. Further, North America is projected to continue its dominance over the forecast period owing to the high percentage of adults with obesity in the region. As per the U.S. Department of Health and Human Services, currently, more than one third of the adult populations are suffering from obesity. Europe anti-obesity drugs market is projected to showcase substantial growth during the forecast period. Rapid rate in growth of overweight and obese population (from 50% in 2008 to 51.6% in 2017) in the European region is expected to fuel the growth of anti-obesity drugs market.

Rise in the Prevalence of Obesity

Increasing number of adults with obesity is anticipated to drive the growth of the anti-obesity

drugs market during the forecast period. Moreover, growing cases of obesity among children across the globe is expected to substantially raise the demand for anti-obesity drugs during the forecast period.

Request For Sample Pages: <u>https://www.researchnester.com/sample-request/2/rep-id-23</u>

Increasing Healthcare Awareness

Rising awareness about obesity impact on the healthcare such as high risk of chronic diseases (hypertension, diabetes and coronary heart diseases) are expected to trigger the demand for anti-obesity drugs market over the forecast period. Further, engagement of government and non-governmental organizations to reduce the obesity and overweight penetration is anticipated to swell the growth of anti-obesity drugs market.

However, high popularity of anti-obesity drug alternatives such as fitness spas & gym and side effects of anti-obesity drugs are likely to inhibit the growth of the global anti-obesity drugs market in the near future.

The report titled "Anti-Obesity Drugs Market : Global Demand Analysis & Opportunity Outlook 2021" delivers detailed overview of the global anti-obesity drugs market in terms of market segmentation by product type, by type and by region.

Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter's five force model.

This report also provides the existing competitive scenario of some of the key players of the global anti-obesity drugs market which includes company profiling of Arena Pharmaceuticals Inc., F. Hoffmann-La Roche Ag, GlaxoSmithKline plc,. Takeda Pharmaceuticals Company Limited, Zafgen, Zydus Cadila, Rhythm Pharmaceuticals, Pfizer Inc., Merck & Co. Inc., Orexigen Therapeutics Inc., Boehringer Ingelheim Gmbh, Eisai Co. Ltd., Novo Nordisk A/S and Norgine B.V. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global anti-obesity drugs market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.

Request For TOC Pages: <u>https://www.researchnester.com/toc-request/1/rep-id-23</u>

Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision so as to avoid future uncertainties.

Request For Buy Now: https://www.researchnester.com/payment/rep-id-23

Ajay Daniel Research Nester +1 646 586 9123 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable

to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.